Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study).

Trial Profile

Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DRTC
  • Most Recent Events

    • 02 May 2017 Status changed from recruiting to discontinued.
    • 31 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 31 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top